241 related articles for article (PubMed ID: 35151370)
1. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.
Nicolas G; Sévigny M; Lecoquierre F; Marguet F; Deschênes A; Del Pelaez MC; Feuillette S; Audebrand A; Lecourtois M; Rousseau S; Richard AC; Cassinari K; Deramecourt V; Duyckaerts C; Boland A; Deleuze JF; Meyer V; Clarimon Echavarria J; Gelpi E; Akiyama H; Hasegawa M; Kawakami I; Wong TH; Van Rooij JGJ; Van Swieten JC; Campion D; Dutchak PA; Wallon D; Lavoie-Cardinal F; Laquerrière A; Rovelet-Lecrux A; Sephton CF
Acta Neuropathol Commun; 2022 Feb; 10(1):20. PubMed ID: 35151370
[TBL] [Abstract][Full Text] [Related]
2. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
[TBL] [Abstract][Full Text] [Related]
3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
4. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
[TBL] [Abstract][Full Text] [Related]
5. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
6. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
8. Rapidly progressive Fronto-temporal dementia (FTD) associated with Frontotemporal lobar degeneration (FTLD) in the presence of Fused in Sarcoma (FUS) protein: a rare, sporadic, and aggressive form of FTD.
Bradfield NI; McLean C; Drago J; Darby DG; Ames D
Int Psychogeriatr; 2017 Oct; 29(10):1743-1746. PubMed ID: 28660843
[TBL] [Abstract][Full Text] [Related]
9. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
[TBL] [Abstract][Full Text] [Related]
10. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
Dormann D; Haass C
Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
[TBL] [Abstract][Full Text] [Related]
11. Neuropathological background of phenotypical variability in frontotemporal dementia.
Josephs KA; Hodges JR; Snowden JS; Mackenzie IR; Neumann M; Mann DM; Dickson DW
Acta Neuropathol; 2011 Aug; 122(2):137-53. PubMed ID: 21614463
[TBL] [Abstract][Full Text] [Related]
12. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
A Armstrong R
Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
[TBL] [Abstract][Full Text] [Related]
13. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
[TBL] [Abstract][Full Text] [Related]
14. HnRNP Pathologies in Frontotemporal Lobar Degeneration.
Jiang X; Gatt A; Lashley T
Cells; 2023 Jun; 12(12):. PubMed ID: 37371103
[TBL] [Abstract][Full Text] [Related]
15. The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions.
Gami-Patel P; Bandopadhyay R; Brelstaff J; Revesz T; Lashley T
Neurobiol Aging; 2016 Oct; 46():192-203. PubMed ID: 27500866
[TBL] [Abstract][Full Text] [Related]
16. Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS.
Motaln H; Čerček U; Yamoah A; Tripathi P; Aronica E; Goswami A; Rogelj B
Brain; 2023 Oct; 146(10):4088-4104. PubMed ID: 37071594
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
[TBL] [Abstract][Full Text] [Related]
18. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
[TBL] [Abstract][Full Text] [Related]
20. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
